'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC

Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.

Related Keywords

Tennessee ,United States ,Boston ,Massachusetts ,Australia ,Chicago ,Illinois ,Melbourne ,Victoria ,American ,Jessicaj Lin ,Davidr Spigel , ,European Society For Medical Oncology Virtual Congress ,Peter Maccallum Cancer Centre ,Sarah Cannon Research Institute ,American Society Of Clinical Oncology ,Harvard Medical School ,Drug Administration ,Pfizer ,Benjamin Solomon ,Clinical Oncology ,Lung Medical Oncology ,Medscape Medical News ,Medical Oncology Virtual Congress ,Thoracic Cancers ,Massachusetts General Hospital ,Comparator Drug ,